CA2332505A1 - Composes a affinite pour le recepteur de 5ht7 serotoninergique, destines au traitement de troubles oculaires et du systeme nerveux central - Google Patents

Composes a affinite pour le recepteur de 5ht7 serotoninergique, destines au traitement de troubles oculaires et du systeme nerveux central Download PDF

Info

Publication number
CA2332505A1
CA2332505A1 CA002332505A CA2332505A CA2332505A1 CA 2332505 A1 CA2332505 A1 CA 2332505A1 CA 002332505 A CA002332505 A CA 002332505A CA 2332505 A CA2332505 A CA 2332505A CA 2332505 A1 CA2332505 A1 CA 2332505A1
Authority
CA
Canada
Prior art keywords
3alkyl
substituted
substituted optionally
unsubstituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002332505A
Other languages
English (en)
Inventor
Thomas R. Dean
Jesse A. May
Najam A. Sharif
Hwang-Hsing Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2332505A1 publication Critical patent/CA2332505A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés possédant une affinité à l'égard du récepteur de 5HT¿7? (dont certains sont nouveaux), utiles pour abaisser la tension intra-oculaire, pour améliorer l'écoulement sanguin vers la tête du nerf optique et la rétine, pour apporter une protection neurologique et traiter des maladies de la rétine. Ces composés sont également utiles pour traiter les troubles du sommeil, la dépression ainsi que d'autres troubles psychiatriques tels que la schizophrénie, l'anxiété, les troubles obsessifs impulsifs, les troubles du rythme circadien, ainsi que l'hypertension d'origine centrale ou périphérique. L'invention concerne encore des compositions et des procédés destinés à l'emploi de ces composés.
CA002332505A 1998-05-19 1999-05-10 Composes a affinite pour le recepteur de 5ht7 serotoninergique, destines au traitement de troubles oculaires et du systeme nerveux central Abandoned CA2332505A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US8600698P 1998-05-19 1998-05-19
US8600598P 1998-05-19 1998-05-19
US8598998P 1998-05-19 1998-05-19
US8600298P 1998-05-19 1998-05-19
US60/085,989 1998-05-19
US60/086,002 1998-05-19
US60/086,006 1998-05-19
US60/086,005 1998-05-19
PCT/US1999/010179 WO1999059499A2 (fr) 1998-05-19 1999-05-10 Composes a affinite pour le recepteur de 5ht7 serotoninergique, destines au traitement de troubles oculaires et du systeme nerveux central

Publications (1)

Publication Number Publication Date
CA2332505A1 true CA2332505A1 (fr) 1999-11-25

Family

ID=27491993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002332505A Abandoned CA2332505A1 (fr) 1998-05-19 1999-05-10 Composes a affinite pour le recepteur de 5ht7 serotoninergique, destines au traitement de troubles oculaires et du systeme nerveux central

Country Status (7)

Country Link
EP (1) EP1079763A2 (fr)
JP (1) JP2002515408A (fr)
CN (1) CN1301161A (fr)
AU (1) AU3978899A (fr)
BR (1) BR9910590A (fr)
CA (1) CA2332505A1 (fr)
WO (1) WO1999059499A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9828004D0 (en) * 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
WO2000069437A1 (fr) 1999-05-18 2000-11-23 Synaptic Pharmaceutical Corporation Utilisation d'agonistes ou d'antagonistes vis-a-vis du recepteur 5-ht7 pour traiter les troubles de la vessie
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
PL358481A1 (en) * 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
KR20030095183A (ko) * 2000-03-17 2003-12-18 알콘, 인코퍼레이티드 녹내장 치료용 5-하이드록시 인다졸 유도체
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
JP2006511556A (ja) 2002-12-13 2006-04-06 アルコン，インコーポレイテッド 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
TW200520760A (en) 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor

Also Published As

Publication number Publication date
WO1999059499A2 (fr) 1999-11-25
CN1301161A (zh) 2001-06-27
JP2002515408A (ja) 2002-05-28
WO1999059499A3 (fr) 2000-03-16
EP1079763A2 (fr) 2001-03-07
AU3978899A (en) 1999-12-06
BR9910590A (pt) 2001-01-23

Similar Documents

Publication Publication Date Title
WO1999032481A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
CA2332505A1 (fr) Composes a affinite pour le recepteur de 5ht7 serotoninergique, destines au traitement de troubles oculaires et du systeme nerveux central
JPH04295477A (ja) 緑内障処置のための置換ピラジン、ピリミジン、ピリダジン類
US20050176765A1 (en) Ophthalmic compositions for treating ocular hypertension
JPH0637488B2 (ja) チオフエンスルホンアミド抗緑内障剤
JP2010024243A (ja) 緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体
US7285553B2 (en) Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
JP2010095550A (ja) キノリン誘導体
AU2002346671B2 (en) Aminoalkyl-benzofuran-5-OL compounds for the treatment of glaucoma
JP2007297283A (ja) 新規桂皮酸関連化合物
KR20040101563A (ko) 5-ｈｔ-2ｃ 수용체 길항제로 유용한 인돌린 유도체를포함하는 약제 조성물
AU2001216034B2 (en) Pyranoindoles for treating glaucoma
US5538966A (en) Carbonic anhydrase inhibitors
US6399614B1 (en) 1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring
KR20000029564A (ko) 5ＨＴ2ｃ길항제및Ｄ2길항제를함유하는약제학적조성물
US6057334A (en) Benzo[g]quinoline derivatives
AU2002328856A1 (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia
US7439262B1 (en) Substituted 1-alkylamino-1-H-indazoles for the treatment of glaucoma
JPS62116575A (ja) 置換チオフエン−２−スルホンアミド抗緑内障剤
MXPA00011211A (en) Serotonergic 5ht7
JPH06102664B2 (ja) 局所的に有効なカルボニツクアンヒドラーゼ阻害剤としての５―カルバモイルチエノ〔２，３―ｂ〕チオフエン―２―スルホンアミド類及び製造方法
KR100486795B1 (ko) 5-ht-2c수용체길항제로유용한인돌린유도체
WO1995019981A1 (fr) Procede de preparation de derives du thienothiazine sulfonamide, intermediaires de preparation, et utilisation comme inhibiteurs d'anhydrases carboniques
WO1999032443A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
ZA200406493B (en) Quinoline derivatives.

Legal Events

Date Code Title Description
FZDE Dead